Tags : Biologic Study

Takeda Reports Results of Vedolizumab in its First Head-to-Head Biologic

Tuba Khan September 26, 2019

Shots: The P-IIIb VARSITY study involves assessing of Entyvio (vedolizumab, IV) vs Humira (adalimumab, SC) in 769 patients (anti-TNFα-naïve patients & anti-TNFα-experienced patients) with moderately to severely active UC for […]readmore

Tags : Biologic Study

Takeda Reports Results of Vedolizumab in its First Head-to-Head Biologic

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Biologic Study

﻿Takeda Reports Results of Vedolizumab in its First Head-to-Head Biologic

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Takeda Reports Results of Vedolizumab in its First Head-to-Head Biologic